{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:46:36Z","timestamp":1792003596416,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ajo.2012.12.009","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T15:00:54Z","timestamp":1360162854000},"page":"804-813.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Application for Tacrolimus Ointment in Treating Refractory Inflammatory Ocular Surface Diseases"],"prefix":"10.1016","volume":"155","author":[{"given":"Young Ji","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Woong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Yul","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ico.0000151507.49565.6e","article-title":"Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders","volume":"24","author":"Joseph","year":"2005","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.ajo.2012.12.009_bib2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"issue":"7","key":"10.1016\/j.ajo.2012.12.009_bib3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14656566.2.7.1167","article-title":"Topical tacrolimus for the treatment of inflammatory skin diseases","volume":"2","author":"Assmann","year":"2001","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.ajo.2012.12.009_bib4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.139.6.1797","article-title":"Novel immunosuppressive agent, FK506. In\u00a0vitro effects on the cloned T\u00a0cell activation","volume":"139","author":"Sawada","year":"1987","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.ajo.2012.12.009_bib5","first-page":"2737","article-title":"Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye","volume":"34","author":"Pleyer","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2012.12.009_bib6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: a further update of its use in the management of organ transplantation","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ajo.2012.12.009_bib7","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1365-2133.2008.08813.x","article-title":"Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study","volume":"159","author":"Thaci","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ajo.2012.12.009_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2340\/00015555-0803","article-title":"One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial","volume":"90","author":"Mandelin","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.ajo.2012.12.009_bib9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":"Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICO.0b013e3181d83875","article-title":"Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature","volume":"30","author":"Garcia","year":"2011","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.ajo.2012.12.009_bib11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/sj.eye.6702367","article-title":"Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis","volume":"21","author":"Nivenius","year":"2007","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.ajo.2012.12.009_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease","volume":"135","author":"Rikkers","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1468-3083.2008.02933.x","article-title":"Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids","volume":"23","author":"Zribi","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ajo.2012.12.009_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ICO.0b013e318159afbb","article-title":"Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis","volume":"27","author":"Kymionis","year":"2008","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.ajo.2012.12.009_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-0420.2006.00699.x","article-title":"Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study","volume":"84","author":"Virtanen","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"10.1016\/j.ajo.2012.12.009_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","article-title":"Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment","volume":"113","author":"Vichyanond","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.ajo.2012.12.009_bib17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2009.249","article-title":"Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD","volume":"45","author":"Tam","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ICO.0b013e3181606086","article-title":"Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty","volume":"27","author":"Dhaliwal","year":"2008","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.ajo.2012.12.009_bib19","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/ICO.0b013e318243f69d","article-title":"Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis","volume":"31","author":"Kymionis","year":"2012","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.ajo.2012.12.009_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":"Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study","volume":"33","author":"Attas-Fox","year":"2008","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.ajo.2012.12.009_bib21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/01.ico.0000127484.46584.f6","article-title":"Treatment of atopic eyelid disease using topical tacrolimus following corticosteroid discontinuation in a patient with open-angle glaucoma","volume":"23","author":"Kymionis","year":"2004","journal-title":"Cornea"},{"issue":"11","key":"10.1016\/j.ajo.2012.12.009_bib22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/archophthalmol.2009.263","article-title":"Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits","volume":"127","author":"Liang","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.12.009_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ajo.2012.12.009_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/ICO.0b013e31822481c2","article-title":"Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis","volume":"31","author":"Tzu","year":"2012","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.ajo.2012.12.009_bib25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","article-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2012.12.009_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1546-0096-9-34","article-title":"Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series","volume":"9","author":"Taddio","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib27","first-page":"207","article-title":"Effect of topical FK506 used alone or combined with keratoplasty on patients with recurrent Mooren's corneal ulcer","volume":"22","author":"Xie","year":"2006","journal-title":"Yan Ke Xue Bao"},{"issue":"8","key":"10.1016\/j.ajo.2012.12.009_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":"Clinical treatment of dry eye using 0.03% tacrolimus eye drops","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ajo.2012.12.009_bib30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.135.5.574","article-title":"Tacrolimus: the drug for the turn of the millennium?","volume":"135","author":"Ruzicka","year":"1999","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ajo.2012.12.009_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1076\/ocii.6.1.51.8079","article-title":"Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis","volume":"6","author":"Whitcup","year":"1998","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00003226-199507000-00010","article-title":"Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management","volume":"14","author":"Messmer","year":"1995","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2012.12.009_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2011.07.043","article-title":"Scleritis therapy","volume":"119","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2012.12.009_bib34","first-page":"7","article-title":"Mooren's ulcer: current concepts in management","volume":"45","author":"Sangwan","year":"1997","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ajo.2012.12.009_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000099270","article-title":"Cicatrizing and autoimmune diseases","volume":"92","author":"Rashid","year":"2007","journal-title":"Chem Immunol Allergy"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000177430.89645.6d","article-title":"Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome","volume":"45","author":"Hynes","year":"2005","journal-title":"Int Ophthalmol Clin"},{"issue":"4","key":"10.1016\/j.ajo.2012.12.009_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.ajo.2012.12.009_bib38","first-page":"27","article-title":"Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis","volume":"73","author":"Patterson","year":"1994","journal-title":"Ann Allergy"},{"issue":"6","key":"10.1016\/j.ajo.2012.12.009_bib39","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.12.009_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjo.2006.097428","article-title":"Tacrolimus immunosuppression in high-risk corneal grafts","volume":"91","author":"Joseph","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.12.009_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00003226-200403000-00013","article-title":"Kaposi varicelliform eruption associated with 0.1% tacrolimus ointment treatment in atopic blepharitis","volume":"23","author":"Miyake-Kashima","year":"2004","journal-title":"Cornea"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293941200863X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293941200863X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:07:03Z","timestamp":1757596023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293941200863X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S000293941200863X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2012.12.009","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application for Tacrolimus Ointment in Treating Refractory Inflammatory Ocular Surface Diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2012.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}